# Base editing Base editors (CBE/ABE) make single-nucleotide changes C·G→T·A and A·T→G·C without double-strand breaks — treating monogenic disease (sickle cell, beta-thalassemia) at up to 90% efficiency with no indels. Source: https://en.bioecon.ru/technology/base-editing/ Updated: 2026-09-02 ## Overview and value chain Markers: [EC: ATMP Regulation (EC No 1394/2007) | OECD: Bio-Pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)] Base editing makes a single-nucleotide change with no double-strand break (DSB) and no indel risk: a chimeric protein fuses catalytically dead Cas9 (dCas9) or nickase nCas9 to a DNA deaminase. Cytidine editors (CBE) convert C· G to T· A; adenine editors (ABE) convert A· T to G· C. The absence of DSB rules out the large chromosomal rearrangements and karyotype chaos of classic Cas9. First ABE clinical trials showed up to 90% correction with minimal off-targets — for sickle-cell disease, beta-thalassemia, progeria. Key platforms of base editing: 1. **Cytidine editors (CBE):** C· G to T· A (APOBEC/AID deaminases). 2. **Adenine editors (ABE):** A· T to G· C (TadA*8e, k_cat > 10 s⁻¹). 3. **Nickase nCas9 (D10A):** a single-strand nick on the unedited strand drives repair. 4. **RNP/LNP delivery:** pre-formed ribonucleoproteins or mRNA in lipid nanoparticles. ### Sectoral value chain ``` [gRNA design + deaminase choice] ──> [CBE/ABE expression + purification] ──> [mRNA/RNP + LNP formulation] │ (cell delivery) │ ▼ [QC: accuracy + off-target] <─── [deep sequencing] <─── [targeted deamination] ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Editor Design** | gRNA choice, deaminase, narrow window (1–2 nt) | **In:** target. **Out:** editor design. | | **Protein Expression** | E. coli producer of nCas9-deaminase (e.g. TadA*8e) | **In:** constructs, media. **Out:** lysate. | | **Purification** | Ni-NTA + ion-exchange chromatography to >98% | **In:** lysate. **Out:** pure CBE/ABE. | | **sgRNA + RNP Assembly** | sgRNA synthesis (OligoPilot), RNP assembly 1{:}1.2 | **In:** protein, sgRNA. **Out:** RNP complex. | | **Delivery (ex vivo / in vivo)** | MaxCyte electroporation into CD34^+ or LNP | **In:** RNP, cells. **Out:** edited cells. | | **Genome QC** | Amplicon-seq — target change, no indels/off-target | **In:** cell DNA. **Out:** editing report. | Cross-cutting technologies of the sector: - **Narrow window (narrow-window):** mutant deaminases active over 1–2 nt — no bystander editing. - **RNP delivery:** pre-formed RNPs for short activity and minimal off-targets. - **CBE+ABE tandems:** dual editors for several base changes at once. --- ## US The US holds the key patents (David Liu lab, Harvard/Broad) and leads in the clinic. ### Beam Therapeutics, Prime Medicine, FDA deep-sequencing oversight - **Beam Therapeutics:** key ABE/CBE patents, BEAM-101 (sickle-cell disease). - **Prime Medicine:** hybrid Prime+Base platforms for neurodegeneration. - **FDA:** detailed deep sequencing of target loci post-therapy; delivery biosafety oversight. --- ## CN China is one of the leaders by number of Base Editing clinical trials. ### EdiGene, Wenzhou Medical University, NMPA orphan-disease fast-track - **EdiGene:** domestic editors, haematology clinical trials. - **Wenzhou Medical University:** high-precision BE for inherited blindness; prenatal editing. - **NMPA:** subsidies and simplified phase-1 protocols for orphan diseases. --- ## EU The EU leads in deaminase-nCas9 structural biology and ex-vivo virus-free delivery. ### Max Planck, DKFZ/DE-DK-FR, EMA long-term safety - **Max Planck Institute:** nCas9-deaminase crystallography, thermostable deaminases. - **DE/DK/FR labs:** virus-free editor delivery into blood stem cells ex vivo. - **EMA:** long-term culture of edited cells before transplantation. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Beam Therapeutics** | 🇺🇸 USA | *BEAM-101* (ABE/CBE) | key ABE/CBE patents, clinical | Scaling | | **Prime Medicine** | 🇺🇸 USA | Prime+Base hybrids | precise neurodegeneration editing | Scaling | | **EdiGene** | 🇨🇳 China | domestic BE editors | haematology clinical trials | Scaling | | **Wenzhou Medical University** | 🇨🇳 China | BE for inherited blindness | prenatal editing | Research | | **Max Planck Institute** | 🇩🇪 Germany | nCas9-deaminase structural biology | thermostable deaminases | Research | | **Broad Institute** | 🇺🇸 USA | birthplace of base editing (D. Liu lab) | ultra-precise deaminases | Research | --- ## Tech stack and innovations The stack rests on evolved deaminases, nCas9 nickase and analytics. 1. **TadA*8e (ABE deaminase):** - a super-fast evolved tRNA deaminase on single-stranded DNA, k_cat > 10 s⁻¹. 2. **Nickase nCas9 (D10A):** - a single-strand nick on the unedited strand drives repair off the edited strand. 3. **Analytics:** - Illumina MiSeq + Oxford Nanopore GridION (long-deletion detection); Benchling for sgRNA design. --- ## Value chains and production pipelines ### RNP production and QC pipeline for base editors (cGMP) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. ABE/CBE expression │ ───> │ 2. Purification (Ni-NTA,IEX)│ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. RNP assembly (1:1.2) │ <─── │ 3. sgRNA synthesis │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. CD34+ electroporation │ ───> │ 6. Amplicon-seq QC │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Protein expression An E. coli producer over-expresses the chimeric protein (e.g. nCas9-TadA*8e for ABE) in a fermenter. #### Stage 2: Protein purification Lysis, Ni-NTA metal-affinity + ion-exchange chromatography to >98% purity. #### Stage 3: sgRNA synthesis Chemical synthesis of the guide RNA with modifications on OligoPilot. #### Stage 4: RNP assembly ABE/CBE protein and sgRNA are mixed at 1{:}1.2 at room temperature for self-assembly. #### Stage 5: Ex-vivo electroporation RNPs are electroporated into autologous CD34^+ stem cells on MaxCyte GTx. #### Stage 6: Genome QC Amplicon-seq verifies the target change and the absence of indels/off-targets before transplantation.